Kurs
-0,48%
Likviditet
1,86 MNOK
Kalender
Tid* | ||
2026-02-19 | 13:00 | Bokslutskommuniké 2025 |
2025-11-19 | 07:00 | Kvartalsrapport 2025-Q3 |
2025-08-20 | 07:00 | Kvartalsrapport 2025-Q2 |
2025-05-21 | 07:00 | Kvartalsrapport 2025-Q1 |
2025-05-20 | N/A | Årsstämma |
2025-02-26 | 13:00 | Bokslutskommuniké 2024 |
2024-11-13 | - | Kvartalsrapport 2024-Q3 |
2024-10-10 | - | Extra Bolagsstämma 2024 |
2024-08-21 | - | Kvartalsrapport 2024-Q2 |
2024-05-30 | - | Split BGBIO 100:1 |
2024-05-29 | - | Kvartalsrapport 2024-Q1 |
2024-05-24 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2024-05-23 | - | Årsstämma |
2024-02-14 | - | Bokslutskommuniké 2023 |
2023-11-14 | - | Kvartalsrapport 2023-Q3 |
2023-08-23 | - | Kvartalsrapport 2023-Q2 |
2023-06-22 | - | Kvartalsrapport 2023-Q1 |
2023-05-22 | - | Årsstämma |
2023-04-21 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-15 | - | Kvartalsrapport 2022-Q3 |
2022-08-23 | - | Kvartalsrapport 2022-Q2 |
2022-05-24 | - | Kvartalsrapport 2022-Q1 |
2022-04-29 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2022-04-28 | - | Årsstämma |
2022-02-16 | - | Bokslutskommuniké 2021 |
2022-01-06 | - | Extra Bolagsstämma 2022 |
2021-11-16 | - | Kvartalsrapport 2021-Q3 |
2021-08-17 | - | Kvartalsrapport 2021-Q2 |
2021-05-19 | - | Kvartalsrapport 2021-Q1 |
2021-03-22 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2021-03-19 | - | Årsstämma |
2021-02-10 | - | Bokslutskommuniké 2020 |
2020-12-09 | - | Extra Bolagsstämma 2020 |
2020-11-17 | - | Kvartalsrapport 2020-Q3 |
2020-08-18 | - | Kvartalsrapport 2020-Q2 |
2020-05-19 | - | Kvartalsrapport 2020-Q1 |
2020-03-17 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2020-03-16 | - | Årsstämma |
2020-02-11 | - | Bokslutskommuniké 2019 |
2019-11-19 | - | Kvartalsrapport 2019-Q3 |
2019-08-19 | - | Kvartalsrapport 2019-Q2 |
2019-05-08 | - | Kvartalsrapport 2019-Q1 |
2019-03-14 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2019-03-13 | - | Årsstämma |
2019-02-19 | - | Bokslutskommuniké 2018 |
2018-11-13 | - | Kvartalsrapport 2018-Q3 |
2018-08-21 | - | Kvartalsrapport 2018-Q2 |
2018-05-15 | - | Kvartalsrapport 2018-Q1 |
2018-05-15 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2018-05-14 | - | Årsstämma |
2018-03-09 | - | Extra Bolagsstämma 2018 |
2018-02-13 | - | Bokslutskommuniké 2017 |
2017-11-17 | - | Kvartalsrapport 2017-Q3 |
2017-08-18 | - | Kvartalsrapport 2017-Q2 |
2017-05-23 | - | Kvartalsrapport 2017-Q1 |
2017-03-23 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2017-03-22 | - | Årsstämma |
2016-06-22 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2016-06-21 | - | Årsstämma |
2015-06-23 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2015-06-22 | - | Årsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
Bergen, Norway - 7 April 2022- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2021 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS).
The Annual Report for 2021 and ESEF file are attached to this release and are also available on BerGenBio ASA's website https://www.bergenbio.com/investors/reports/
Contacts:
For BerGenBio: Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic tests to potentially identify patient populations most likely to benefit from AXL inhibition: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.